Aeterna Zentaris: Abstract on Diagnostic Use of Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, to be Presented at Upcoming International Congress of Neuroendocrinology

Thursday, July 8, 2010 General News J E 4
QUEBEC CITY, July 8 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 7th International Congress of Neuroendocrinology, which will be held July 11 through 15, 2010, in Rouen, France. AEZS-130 (Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at Title: "Use of the Orally Active Ghrelin Mimetic AEZS-130 as a Simple Test for the Diagnosis of Growth Hormone (GH) Deficiency (GHD) in adults (AGHD)", Merriam G.R., Yuen K., Bonert V., Dobs A, Garcia J., Kipnes M., Molitch M., Swerdloff R., Wang C., Cook d., Altemose I. and Biller B. Presenter: George R. Merriam, M.D., Professor of Medicine, University of Washington Date and Time: Wednesday, July 14, 2010, 3:30 pm -6 pm (local time) Poster Board #: P2-98 Location: Law Faculty, Universite de Rouen



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
A Guide to Passionate Living: Author Shares Secret...
Elsevier and Legacy Interactive(R) Partner to Laun...